JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Alcon Inc

Closed

SectorHealthcare

84.66 -1.24

Overview

Share price change

24h

Current

Min

84.49

Max

85.68

Key metrics

By Trading Economics

Income

76M

350M

Sales

-29M

2.5B

P/E

Sector Avg

39.031

34.393

Dividend yield

0.38

Profit margin

14.153

Employees

25,000

EBITDA

-226M

463M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+24.44% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.38%

2.54%

Next Earnings

19 sie 2025

Market Stats

By TradingEconomics

Market Cap

3.6B

44B

Previous open

85.9

Previous close

84.66

News Sentiment

By Acuity

50%

50%

162 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Alcon Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

5 sie 2025, 10:10 UTC

Acquisitions, Mergers, Takeovers

Alcon to Buy Staar Surgical for $1.5 Billion

14 maj 2025, 15:56 UTC

Earnings
Major Market Movers

Alcon Shares Fall After Lowering 2025 Outlook

26 mar 2025, 21:22 UTC

Acquisitions, Mergers, Takeovers

Alcon Buys Majority Stake in Aurion to Advance Eye Disease Treatment

24 mar 2025, 12:36 UTC

Acquisitions, Mergers, Takeovers

Alcon to Buy Lensar in Deal Worth Up to $430 Million

8 sie 2025, 13:40 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Staar Surgical's Top Holder Questions Deal -- Market Talk

5 sie 2025, 05:07 UTC

Acquisitions, Mergers, Takeovers

Alcon Deal Puts STARR Equity Value at Approximately $1.5 Billion. >ALC.EB

5 sie 2025, 05:07 UTC

Acquisitions, Mergers, Takeovers

Alcon Will Purchase All Outstanding Shares of STAAR Common Stock for $28 Per Share in Cash >ALC.EB

5 sie 2025, 05:07 UTC

Acquisitions, Mergers, Takeovers

Alcon Deal Represents 51% Premium to Closing Price of STAAR Common Stock on Aug. 4 >ALC.EB

5 sie 2025, 05:07 UTC

Acquisitions, Mergers, Takeovers

Alcon Agrees to Acquire STAAR Surgical >ALC STAA

5 sie 2025, 05:01 UTC

Acquisitions, Mergers, Takeovers

Alcon Agrees To Acquire STAAR Surgical >ALC STAA

7 lip 2025, 12:00 UTC

Acquisitions, Mergers, Takeovers

Alcon To Acquire LumiThera And Its Photobiomodulation Device For The Treatment Of Early And Intermediate Dry Age-Related Macular Degeneration (AMD) >ALC

30 maj 2025, 06:32 UTC

Market Talk
Earnings

Alcon's First FDA Approval Since Listing Is Positive, But Expected -- Market Talk

22 maj 2025, 20:46 UTC

Acquisitions, Mergers, Takeovers

Alcon and Lensar Receive FTC Requests for Additional Information About Merger

13 maj 2025, 20:32 UTC

Earnings

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

13 maj 2025, 20:31 UTC

Earnings

Alcon 1Q Sales $2.45B >ALC.EB

13 maj 2025, 20:30 UTC

Earnings

Alcon 1Q Rev $2.47B >ALC.EB

13 maj 2025, 20:30 UTC

Earnings

Alcon 1Q EPS 70c >ALC.EB

8 kwi 2025, 08:20 UTC

Market Talk

Med-Tech Investors Seek 'Safe Havens' Amid Tariff Fears -- Market Talk

26 mar 2025, 21:55 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Alcon Deal for Aurion Follows 2022 Investment, 2024 Lawsuit -- Market Talk

26 mar 2025, 20:33 UTC

Acquisitions, Mergers, Takeovers

Aurion Board Appoints Arnaud Lacoste as CEO of Aurion

26 mar 2025, 20:32 UTC

Acquisitions, Mergers, Takeovers

Alcon: Aurion Will Operate as a Separate Company With Full Support From Alcon to Advance Its Clinical-Stage Allogeneic Cell Therapy Asset

26 mar 2025, 20:32 UTC

Acquisitions, Mergers, Takeovers

Leverages Alcon's Global Scale With Aurion's Cell Therapy Expertise to Accelerate U.S. Phase 3 Development in Fall of 2025 >ALC.EB

26 mar 2025, 20:31 UTC

Acquisitions, Mergers, Takeovers

Alcon Acquires Interest in Aurion to Advance Innovative Cell Therapy for Corneal Endothelial Disease >ALC.EB

26 mar 2025, 20:31 UTC

Acquisitions, Mergers, Takeovers

Alcon Inc. Unit Alcon Research Previously Sued Aurion to Prevent It From Going Public

26 mar 2025, 20:31 UTC

Acquisitions, Mergers, Takeovers

Alcon Acquires Majority Interest in Aurion Biotech >ALC.EB

26 mar 2025, 20:30 UTC

Acquisitions, Mergers, Takeovers

Alcon Acquires Majority Interest in Aurion Biotech

24 mar 2025, 12:21 UTC

Acquisitions, Mergers, Takeovers

Alcon to Buy Lensar in Deal Worth Up to $430M

24 mar 2025, 12:05 UTC

Acquisitions, Mergers, Takeovers

Alcon: Transaction Is Anticipated to Close in Mid-To-Late 2025 >ALC

24 mar 2025, 12:05 UTC

Acquisitions, Mergers, Takeovers

Alcon: Transaction Represents a Total Consideration of Up to About $430M >ALC

24 mar 2025, 12:04 UTC

Acquisitions, Mergers, Takeovers

Alcon: Additional Non-Tradeable Contingent Value Right Offering Up to $2.75 Per Shr in Cash, Conditioned on Achievement of 614,000 Cumulative Procedures With LENSAR's Products Between Jan 1, 2026, and Dec 31, 2027 >ALC

Peer Comparison

Price change

Alcon Inc Forecast

Price Target

By TipRanks

24.44% upside

12 Months Forecast

Average 106.71 USD  24.44%

High 123.933 USD

Low 84 USD

Based on 15 Wall Street analysts offering 12 month price targets forAlcon Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

15 ratings

12

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

95.77 / 97.61Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

162 / 374 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Alcon Inc

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.